The company is expected to report a loss of 40 cents per share during 2010 fourth quarter, compared to loss of 49 cents per share and 46 cents per share in the year-ago and quarter-ago periods, respectively, as per Analysts polled by Bloomberg. For the full year, loss per share is forecast at $1.55 cents for 2010 in comparison to loss of $1.68 per share for 2009. Analysts estimate the company to turn profitable in 2011 on earnings of 2 cents per share. The return-on-equity during the past 12 months has been 25.2%. In comparison, Pfizer, Biogen Idec ( BIIB), Endo Pharmaceuticals ( ENDP) and OXiGENE ( OXGN) have ROEs of 11.7%, 17.2%, 19.7% and -279.7%, respectively. All the five analysts covering the stock recommend buying and estimate the stock to gain around 143% over the next 12 months with a consensus target price of $12.0.